Car driving on road from above
NEWS FROM ALNYLAM

Here you can find the latest press releases from Alnylam.

PDF icon
Download PDF ›80.48 KB
July 23, 2019
Alnylam launches the first ever RNAi therapeutic approved in Canada80.48 KB
PDF icon
Download PDF ›1.29 MB
May 15, 2019
Harnessing RNAi: Alnylam Pharmaceuticals is conquering rare diseases one drug at a time1.29 MB
PDF icon
Download PDF ›269.41 KB
November 26, 2018
Alnylam Pharmaceuticals: Bringing groundbreaking gene silencing therapies to Ontario.269.41 KB
PDF icon
Download PDF ›95.3 KB
September 24, 2018
Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy95.3 KB

GET IN TOUCH

Questions, concerns, or comments about this content? We encourage you to reach out to our team.

Contact us ›

OTHER INQUIRIES

Media: media@alnylam.com

Investor Relations: investors@alnylam.com

General: info@alnylam.ca